Getinge misses Q3 forecasts, weighed by quality and delivery issues
Q3 adj. EBITA and sales miss analysts' forecasts
Orders keep growing organically at 7.4%
Deliveries restarted after temporary disruptions in Q3, CEO says
Shares fall 6.9% by midday local time
Adds sales miss in paragraph 1, shares and analyst comment in paragraphs 6-7, CEO quotes from interview in paragraphs 4,10,12
By Greta Rosen Fondahn
Oct 18 (Reuters) -Swedish medical equipment maker Getinge GETIb.ST missed forecasts for third-quarter profit and sales on Friday despite strong orders, hit by delivery issues and costs of solving prolonged quality problems.
While the order intake grew for a third consecutive quarter, rising 7.4% organically, temporary delivery disruptions affected the earnings, CEO Mattias Perjos said in a statement.
Getinge last month said industrial inspector TUV Sud had reinstated the European "CE" safety mark for its heart-lung products, but warned supplier and production challenges would hinder deliveries in the third quarter.
"We are back at delivering the products again since the first week of October," Perjos told Reuters.
Getinge is still working to resolve costly quality problems with some of its heart products, which has squeezed margins and dragged its shares since the second quarter of 2023.
Shares in the company, which also makes ventilators and equipment for operating rooms, were down 6.9% by 1004 GMT.
"Getinge results remain volatile, both from quarter to quarter, but also between divisions within the quarter which is likely to result in lower confidence in forecasts," J.P.Morgan analysts said in a note.
Getinge's adjusted earnings before interest, tax and amortisation (EBITA) fell 17% to 903 million Swedish crowns ($85.8 million) in the third quarter, missing analysts' expectations of 1.03 billion crowns.
Acute Care Therapies - Getinge's biggest unit which makes heart and intensive care products and has been most affected by the quality issues - saw orders grow more than 10%, while its adjusted EBITA margin fell to 15.8% from 22.5% a year earlier.
Perjos said demand for the unit's products remained fundamentally good despite the quality problems and ongoing dialogue with the U.S. Food and Drug Administration (FDA).
Getinge said in May it would pause promotional activities for some of its heart and heart-lung products in the U.S., after the FDA advised healthcare facilities to move away from its devices.
Getinge has said its U.S. market share for those products is more than 60%, and Perjos said on Friday there were limited alternatives currently offered by the competitors.
($1 = 10.5279 Swedish crowns)
Reporting by Greta Rosen Fondahn in Gdansk; editing by Milla Nissi
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
